Active Substance: strontium ranelate
Common Name: strontium ranelate
ATC Code: M05BX03
Marketing Authorisation Holder: Les Laboratoires Servier
Active Substance: strontium ranelate
Authorisation Date: 2004-09-21
Therapeutic Area: Osteoporosis, Postmenopausal
Pharmacotherapeutic Group: Drugs for treatment of bone diseases
Treatment of severe osteoporosis in postmenopausal women at high risk for fracture to reduce the risk of vertebral and hip fractures.
Treatment of severe osteoporosis in adult men at increased risk of fracture.
The decision to prescribe strontium ranelate should be based on an assessment of the individual patient's overall risks.
What is Protelos?
Protelos is a medicine that contains the active substance strontium ranelate. It is available as 2-g sachets containing granules that are made up into an oral suspension.
What is Protelos used for?
Protelos is used to treat severe osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and who are at high risk of fracture (broken bones) in the spine and the hip. It is also used to treat severe osteoporosis in men who are at increased risk of fracture.
The medicine can only be obtained with a prescription.
How is Protelos used?
Treatment should only be started by a doctor with experience of treating osteoporosis. As there has been some data showing an increased risk of heart attack with Protelos, the decision to prescribe Protelos should take into account the patient’s individual heart risk.
Protelos is taken as one sachet once a day. The contents of the sachet are added and mixed into a glass of water to form a suspension, which is drunk just after being prepared. Protelos should be taken at least two hours after food, milk, milk products or calcium supplements, preferably at bedtime. Protelos is intended for long-term use. Patients should receive calcium or vitamin D supplements if they are not getting enough from their diet.
How does Protelos work?
Osteoporosis happens when not enough new bone grows to replace the bone that is naturally broken down. Gradually, the bones become thin and fragile, and more likely to break. Osteoporosis is more common in women after the menopause, when the levels of the female hormone oestrogen fall, since oestrogen helps to keep bones healthy. Osteoporosis is also observed in men with ageing.
The active substance in Protelos, strontium ranelate, acts on the bone structure. Once in the gut, strontium ranelate releases strontium, which is absorbed into the bone. Exactly how strontium works in osteoporosis is not fully understood, but it is known to stimulate bone formation and reduce bone breakdown.
How has Protelos been studied?
Protelos has been studied in almost 7,000 elderly women in two large studies. Nearly a quarter of the patients were over 80 years of age. The first study included 1,649 women with osteoporosis who had already had a broken bone in the spine and the second included over 5,000 women whose osteoporosis was affecting the hip. In both studies, Protelos was compared with placebo (a dummy treatment) and the main measure of effectiveness was the reduction in the risk of a new bone break with Protelos. In the first study, this was based on the number of patients who, over three years, developed a new break in the spine, and in the second study, it was based on the number of patients who had a new bone break due to osteoporosis at any site other than the spine.
Protelos has also been compared with placebo in a main study involving 261 male patients at increased risk of having a broken bone. The study looked at changes in the bone density after one year of treatment.
What benefit has Protelos shown during the studies?
In the first study, Protelos reduced the risk of new breaks in the spine by 41% over three years: 21% of the 719 women who took Protelos developed a new break in the spine, compared with 33% of the 723 who took placebo.
Overall, the results of the second study taken alone were insufficient to demonstrate a benefit of Protelos in preventing bone breaks. However, when looking only at women of 74 years of age or older with particularly weak thighbones, the results suggested a reduction of the risk of breaks in the hip with Protelos.
When looking at results of the two studies taken together, fewer women in the Protelos group developed breaks at any site outside the spine (including the hip) than in the placebo group (331 out of 3,295 with Protelos compared with 389 out of 3,256 for placebo). This showed that the risk of broken bones is reduced.
In the study in male patients, the bone density in the lower part of the spine increased by 7% after one year of treatment in patients taking Protelos, compared with an increase of 1.7% in patients taking placebo.
What is the risk associated with Protelos?
The most common side effects with Protelos (seen in between 1 and 10 patients in 100) are headache, disturbances in consciousness (fainting), memory loss, nausea (feeling sick), diarrhoea, dermatitis (inflammation of the skin), eczema (flaky skin rash), venous thromboembolism (blood clots in the veins), increased blood creatine kinase levels (an enzyme found in muscle) and myocardial infarction (heart attack). For the full list of all side effects reported with Protelos, see the package leaflet.
Protelos must not be used in people who are hypersensitive (allergic) to strontium ranelate or any of the other ingredients. It must not be used in patients who have or have had venous thromboembolic events (problems due to the formation of blood clots in the veins, such as in the legs or lungs). It must not be used in people who are temporarily or permanently immobilised, such as people on bed rest or recovering from surgery.
In order to reduce the risk of heart attack, Protelos must also not be used in patients with high blood pressure that is not properly controlled or in patients with a current or past history of any of the following:
- ischaemic heart disease (such as angina or a heart attack);
- peripheral arterial disease (obstruction of the blood flow in the arteries, usually in the legs);
- cerebrovascular disease (diseases affecting the blood vessels in the brain, such as stroke).
Why has Protelos been approved?
The CHMP decided that Protelos’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Other information about Protelos
The European Commission granted a marketing authorisation valid throughout the European Union for Protelos on 21 September 2004.
For more information about treatment with Protelos, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Source: European Medicines Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.